Orexo has appointed Henrik Juuel as its Executive Vice President and CFO. Juuel will be a member of the company's executive management team, succeeding Carl-Johan Blomberg, who will leave Orexo as CFO of the company after a two-year tenure. Blomberg will continue to support Orexo and Juuel in a transition period.
Orexo is entering a new phase with increasing effort towards commercialisation of the company's lead product, Zubsolv (buprenorphine+naloxone) sublingual tablet, which was approved by the FDA earlier in July for use as maintenance treatment for people with opioid dependence. Juuel brings relevant experience from senior international management positions within the life science industry, including positions as CFO for NNE Pharmaplan and GN Resound.